Brief: Qiagen Receives FDA Approval For Companion Diagnostic To Blueprint Medicines’ Ayvakit In Gastrointestinal Stromal Tumors

Qiagen NV

07/08/2023 21:09

Aug 7 (Reuters) - Qiagen NV  QIA.DE :
    * QIAGEN RECEIVES FDA APPROVAL FOR COMPANION DIAGNOSTIC TO
BLUEPRINT MEDICINES’ AYVAKIT® (AVAPRITINIB) IN GASTROINTESTINAL
STROMAL TUMORS

Source text for Eikon:  ID:nGNX4Gw7mj 
Further company coverage:  QIA.DE 

 ((Reuters.Briefs@thomsonreuters.com;))